BIOHIT GROUP INTERIM REPORT Q3/2015
|
|
- David Ferguson
- 8 years ago
- Views:
Transcription
1 Biohit Oyj Interim Report Q3 / 2015
2 BIOHIT GROUP INTERIM REPORT Q3/2015 Biohit Oyj Interim Report, 22 October 2015 at 9:30 am local time (EEST) SUMMARY January September / 2015 Net sales grew by 50.4% compared with January-September 2014 Net sales EUR 4.8 million (EUR 3.2 million) Operating result, continuing operations EUR -1.5* million (EUR -3.3 million) Result for the reporting period, continuing operations EUR -1.5 million (EUR -3.2 million) Result for the reporting period, discontinued operations EUR 0.0 million (EUR 3.3 million) Total result for the reporting period EUR -1.5 million (EUR 0.0 million) Net sales from international operations 88.1% (91.0%) of total net sales Equity ratio 88.0% (89.2%) July September / Q Net sales grew by 12.3% compared with Q3/2014 Net sales EUR 1.3 million (EUR 1.2 million) Operating result, continuing operations EUR -0.0* million (EUR -0.9 million) Result for the reporting period, continuing operations EUR -0.1 million (EUR -0.9 million) Result for the reporting period, discontinued operations EUR 0.0 million (EUR 0.0 million) Total result for the reporting period EUR -0.1 million (EUR -0.9 million) Net sales from international operations 87.8% (92.7%) of total net sales Equity ratio 88.0% (89.2%) * Includes a nonrecurring operating income of EUR 0.7 million from the consolidation of the joint venture. Net sales grew 12.3 % compared with Q3/2014 Equity ratio 88.0 % Net sales from international operations 87.8 % 2
3 PRESIDENT & CEO SEMI KORPELA: During the reporting period, the development of Biohit Oyj s net sales slowed down but however improved compared to January-September The focus of our business development during the third quarter of 2015 was on increasing services sales, expanding the international distributor network and supporting existing partners, for example by launching new products. Additionally and as planned we have continued our work in order to improve advancements in medical practices (incl. cancer screenings) and also to increase public awareness of acetaldehyde. In July, we announced that China started two gastric cancer screening studies using Biohit Oyj s GastroPanel test. The first study of early gastric cancer screening in the National Clinical Research Center for Digestive Diseases (Changhai Hospital), is funded by the Ministry of Science and Technology, which is the organizer of a multi-center study of early gastric cancer risk screening. The study will involve at least 20,000 persons in approximately 50 hospitals. The second study is being conducted in Chinese healthcare centers by the China Health Promotion Foundation. The foundation is a public organisation, managed by the Chinese Ministry of Health. Around half a million year-old asymptomatic persons will be tested in the study. The sample collection has begun in the summer of During the reporting period, in July, the registration of Acetium capsules in China was completed where our partner GrandPharma will begin the sales of Acetium capsules using the Chinese brand name Shubang by the end of the year. We also signed a distributor agreement with Portuguese ARIUM Sistemas de Diagnòstico Lda and it covers the distribution of diagnostic products in Portugal. In July we signed a distributor agreement with Korean Humas covering the distribution of Biohit quick tests. During the reporting period Helicobacter Pylori Quick Tests was registered in Singapore, Helicobacter Pylori UFT300 Quick Test and Helicobacter pylori IgG antibody for ELISA test was registered in Taiwan and many of our Quick Test were registered in Ukraine. In August we signed a distribution agreement with Kuwaiti Health Life covering Biohit Quick Tests. 3
4 In September Acetium product family grew with a new lozenge flavor. The salty liquorice flavored lozenges came into Finnish pharmacies during September-October. In the service sales side, we expanded our product portfolio with a blood sample based vitamin D test and developed our business by introducing an electronic appointment booking service in Finland. In September Biohit Oyj and Daiichi Sankyo (Thailand) Ltd signed a distributor agreement. With the agreement Daiichi Sankyo (Thailand) Ltd gains exclusive rights for the distribution of Acetium capsules in Vietnam, Laos, Cambodia and Myanmar. In September we extended the distribution agreement of Acetium products with Oriola Oy to the Baltic countries. In the Congress of the European Society for Biomedical Research on Alcoholism (ESBRA) held in September, a new study was introduced that assesses the effect of Acetium lozenges on salivary acetaldehyde concentrations after sipping of alcoholic beverages containing high levels of acetaldehyde. Promising results were gained with Acetium lozenge in the elimination of carcinogenic acetaldehyde in saliva. The motion of the European Parliament s committee on Environment, Public Health and Food Safety (ENVI) was accepted in May 2015, containing key elements regarding acetaldehyde. European Parliament urged the Commission to immediately ask the European Food Safety Authority (EFSA) to re-evaluate the use of acetaldehyde as a flavouring substance in alcoholic and non-alcoholic beverages. MEPs Against Cancer, an informal group of Members of the European Parliament, which is committed to actions against cancer held an expert consultation about alcohol and cancer on Wednesday September 16, Experts were present from European cancer organizations umbrella organization European Cancer League and from European Alcohol Policy Alliance Care that coordinates alcohol policy in the member states of the European Union. Our work to increase public awareness of acetaldehyde continues. We achieved a significant milestone in R&D operations during the reporting period when the development of the standardized GastroPanel test was completed. GastroPanel can now be carried out more cost effectively and user-friendly in the primary health care and screening processes. 4
5 CONSOLIDATED KEY FIGURES 7-9/ / / /2014 Net sales (MEUR) Operating profit/loss, continuing operations (MEUR) Profit/loss before taxes (MEUR) Profit/loss for the period, continuing operations (MEUR) Profit/loss for the period, discontinued operations (MEUR) Profit/loss for the period, total (MEUR) Average number of personnel Number of personnel at the end of the period Equity ratio (%) 88.0% 89.2% 88.0% 89.2% Earnings per share, continuing operations (EUR) Earnings per share, discontinued operations diluted (EUR) Shareholders' equity per share (EUR) Average number of shares during the period 14,346,537 14,010,050 14,074,818 13,893,963 Number of shares at the end of the period 14,348,533 14,030,593 14,348,533 14,030,593 REPORTING Biohit's product portfolio consists of diagnostic tests, acetaldehyde-binding products and monoclonal antibodies. The entire product portfolio is reported under a single segment. NET SALES AND RESULT January September Net sales grew by 50.4% compared with 1-9/2014. Shipments for screening studies in China had a positive impact on net sales in the reporting. The operating loss from continuing operations was EUR -1.5 million (EUR -3.3 million 1-9/2014). The result for continuing operations during the reporting period totalled EUR -1.5 million (EUR -3.2 million). The consolidation of the joint venture had a nonrecurring effect of EUR 0.7 million on the operating income. The result for discontinued operations during the reporting period totalled EUR 0.0 million (EUR 3.3 million). In conjunction with the divestment of the liquid handling business in late 2011, EUR 3.5 million of the gains 5
6 on the sale were not recognized due to the terms of the sale agreement and to other, related factors that remained open at the time. The amount was recognised on 31 March 2014, when the deal was closed. The result for the reporting period totalled EUR -1.5 million (EUR 0.0 million). Consolidated net sales and result for continued operations 7-9/ / 2014 Change 1-9/ / 2014 Change 1-12/ 2014 Net sales MEUR Change compared with the previous year (%) 12.3% 50.4% Operating income MEUR Change compared with the previous year (%) 94.7% 54.6% Operating income (% of net sales) -4% -77 % -31% -103% -103% BALANCE SHEET On 30 September 2015, the balance sheet total was EUR 13.3 million (31 December 2014 EUR 14.5 million), and the equity ratio was 88.0% (31 December %). FINANCING Biohit Oyj enjoys a strong financial position, which allows determined investments in an international distributor network as well as the development and commercialization of new products. At the end of the reporting period, the company's financial assets totalled EUR 8.5 million (31 December 2014 EUR 10.4 million). 6
7 RESEARCH AND DEVELOPMENT R&D operations were again focused on innovations, as well as product development and improved usability. Biohit Oyj also employs external experts and subcontractors in its R&D operations. Development expenditure has not been capitalized. Research and development expenditure during the 1 9/2015 reporting period amounted to EUR 1.6 million (EUR 1.5 million). In Finland, the clinical stage of ongoing research project on smoking cessation (with the Acetium lozenge as the research product) will be completed at the end of October. After this the examination of the results can begin. Two research projects on preventing migraine-type headache episodes (with the Acetium capsule as the research product) continue as planned. The development of the new standardized GastroPanel test is completed, and also the results of the first new clinical confirmatory examination of 100 patients are very good. A broader research of over 1000 patients at the Oulu University Hospital (Gastro Center) has received the approval of the Ethical Committee and is set to begin during October. Acetium capsules acetaldehyde-binding properties have been studied in a trial conducted in Sweden, which confirms the earlier scientific results related to Acetium. The studies showed that Acetium binds 60 80% of the group I carcinogenic acetaldehyde and creates a harmless MTCA compound. The report has been sent to be published in a high class scientific journal. Based on the results of a comparative ColonView trial published in the May issue of the international cancer journal, Anticancer Research, the ColonView test exceeds the performance of even the best currently available FIT clinical tests in terms of sensitivity as well as accuracy. A similar, comparative study has proceeded over midpoint at the Barretos cancer hospital in Brazil and preliminary results strengthen this view. GastroPanel testing targeted at the elderly population was carried out during the last reporting period to determine the prevalence of latent B12 vitamin deficiency and its causes (atrophic gastritis) among over 75- year-olds. The results show that the commonness of latent B12 vitamin deficiency among the elderly is at estimated level, but at the same time the results indicate that serious complications related to this deficiency could be prevented with early diagnostics and an appropriate substitution treatment. Ethical permission has now been gained for a similar study in Tartu. The results of the both studies will be reported together, when it can be determined whether or not there are observed population based differences in B12 vitamin levels and in complications arising from a lack of the vitamin. INVESTMENTS Gross investments during the reporting period 1-9/2015 totalled EUR 0.2 million (EUR 0.3 million), of which expenditure during the third quarter was EUR 0.0 million (EUR 0.1 million). 7
8 PERSONNEL During the reporting period 7-9/2015, the average number of personnel employed by the Group was 53 (52) of whom 45 (43) were employed by the parent company and 8 (9) by its subsidiaries. SHORT-TERM RISKS AND UNCERTAINTY FACTORS Biohit s key risks have to do with the investments required for business growth. There are risks involved in areas such as the success of clinical trials, new market areas, the selection and development of distribution channels, personnel recruitment, registration processes, product pricing, and political decision-making affecting the progress of screening programmes. Significant short-term risks are associated with the selection of new market areas, the timing of expansion into selected markets and product success in these markets. The recent increase in uncertainty factors associated with international politics may have an unfavourable impact on the company's business. The duration of the product registration process is different in each market area due to different processing times of local authorities. For this reason, it is not possible to accurately assess the time it takes to handle registrations in these areas and for product sales to begin. When investing liquid assets, the objective is to gain a return on investment with a minimum risk of equity loss. The investment portfolio consists of deposits, money market investments and corporate loans. A fundamental aspect of portfolio management is sufficient diversification across different asset classes, investment instruments and counterparties. Biohit conducts its investment activities with at least two partners. Thanks to its wide customer base, Biohit does not materially depend on any individual customers or project deliveries, with the exception of GastroPanel sales in China, which currently represents a major business for Biohit. Most of the company s business is conducted in euros. 8
9 MAIN EVENTS IN THE REPORTING PERIOD Gastric cancer screening study to start in China A gastric cancer risk screening study started in China, with at least people to be screened with the Biohit Oyj s GastroPanel test, with over 50 hospitals participating. The screenings are set to begin in 2015 and end in December Population-based screening study of asymptomatic persons to start in China, using GastroPanel biomarkers disclosing gastric cancer A gastric cancer risk screening study will be organised in Chinese healthcare centres by the China Health Promotion Foundation. The foundation is a public organisation managed by the Chinese Ministry of Health. The multi-centre study will be conducted by fifty to one hundred primary healthcare units. The screening of around half a million year-old asymptomatic persons will be tested with GastroPanel biomarkers, delivered by Biohit Oyj. Acetium family grew during September Acetium product family grew with a new lozenge flavor. A consumer survey chose salty liquorice as the Finns favorite flavor. In the future, the package color will indicate the flavor. The new flavor is in Finnish pharmacies during September. Biohit Oyj signed a distributor agreement with Daiichi Sankyo Biohit Oyj and Daiichi Sankyo (Thailand) Ltd signed a distributor agreement during the reporting period. The agreement was in force immediately, and Daiichi Sankyo (Thailand) Ltd gained exclusive rights for the distribution of Acetium capsules in Vietnam, Laos, Cambodia and Myanmar. Promising results with Acetium lozenge in the elimination of carcinogenic acetaldehyde in saliva A new study that assesses the effect of Acetium lozenges on salivary acetaldehyde concentrations after sipping of alcoholic beverages containing high levels of acetaldehyde, was introduced in the Congress of the European Society for Biomedical Research on Alcoholism (ESBRA). European parliament s expert consultation on acetaldehyde MEPs Against Cancer, an informal group of Members of the European Parliament, which is committed to actions against cancer held an expert consultation about alcohol and cancer on Wednesday September 16, 9
10 2015. Experts were present from European cancer organizations umbrella organization European Cancer League and from European Alcohol Policy Alliance Eurocare that coordinates alcohol policy in the member states of the European Union. Vitamin D test added to Biohit's Service Laboratory's selection in Finland Biohit Oyj launches a new test for diagnosis of vitamin D deficiency from venous blood samples. The concentration of 25-OH vitamin D in blood is so far the easiest and most reliable indicator of biologically active vitamin D levels. Serum 25-OH vitamin D levels reflect the total vitamin D storage of the body and also correlate with the clinical symptoms of vitamin D deficiency. MAJOR EVENTS AFTER THE END OF THE PERIOD Biohit Oyj launches a new version of the GastroPanel test The GastroPanel test unification project was completed after the reporting period. The result is a new Biohit GastroPanel test family, in which the four biomarkers (pepsinogen I and II, gastrin-17, Helicobacter pylori IgG antibody) will be processed using uniform reagents and reaction conditions. This increases the acceptance of the test and reduces significantly its labor-intensity and overall processing time. 10
11 SHARES AND SHAREHOLDERS Biohit Oyj s number of shares is 14,348,533 of which 2,975,500 (2,975,500) are Series A shares and 11,373,033 (11,340,093) are Series B shares. The Series B shares are quoted on NASDAQ Helsinki in the Small cap/healthcare group under the code BIOBV. Assuming that the market capitalisation for series A and B shares is equal, the total market capitalisation at the end of the period was EUR 71.2 million (EUR 81.3 million). The shares trade value during the period amounted to EUR 16.3 million. BIOBV/NASDAQ OMX Helsinki 1-9/ / /2014 High (EUR) Low (EUR) Average (EUR) Latest (EUR) Turnover (EUR) 16,303,870 22,531,644 25,927,811 Turnover volume 2,947,195 3,385,412 4,028,617 Shareholders At the end of the reporting period on 30 September 2015, the company had 6,764 shareholders (6,822 on 30 September 2014). Private households held 77.9% (78.0%), companies 20.2% (20.2%) and public sector organisations 0.0% (0.0%). Foreign ownership or nominee registrations accounted for 1.7% (1.7%) of shares. Further information on the shares, major shareholders and management shareholdings is available on the company's website at ACCOUNTING PRINCIPLES This interim report has been prepared in accordance with the requirements of the IAS 34 standard. All business operations are presented as one segment. Biohit Oyj has applied the same accounting principles in preparing this interim report as in its financial statements of The IFRS standards or standard interpretations that came into effect in 2015 did not have a material impact on the accounting principles. Joint control in accordance with the IFRS 10 standard fulfilled on part of Biohit Biotech (Hefei) Co. Ltd. by the closing date of 30 September 2015 in the way referred to in the standard and the shareholders agreement and the investment is therefore presented in the balance sheet drawn up according to the new standards and consolidated in Biohit s consolidated financial statements using the equity method. The consolidation had a nonrecurring effect of EUR 0.7 million on the operating income. In the future Biohit Oyj s share of the joint venture s profit/loss will be reported above operating profit. All of the figures in the interim report have been rounded up or down, due to which the sums of figures may deviate from the sum total presented. The figures for the reporting period are unaudited. 11
12 CONSOLIDATED INCOME STATEMENT EUR million 7-9/ 7-9/ 1-9/ 1-9/ 1-12/ Change Change Net sales Materials and services Gross margin Other operating income Sales and marketing Administration Production and product development Operating profit/loss, continuing operations Financial income Financial expenses Profit/loss before taxes Income taxes Income for the period, continuing operations Income for the period, discontinued operations Income for the period, total Available-for-sale financial assets Translation differences Other comprehensive income to be reclassified to profit or loss in subsequent periods Total comprehensive income for the period Earnings per share calculated from earnings attributable to equity holders of the parent company Undiluted earnings per share, continuing operations (EUR) Undiluted earnings per share, discontinued operations (EUR) Diluted earnings per share, discontinued operations (EUR) 1-9/ / /
13 CONSOLIDATED BALANCE SHEET MEUR 30 September September December 2014 ASSETS NON-CURRENT ASSETS Intangible assets Tangible assets Share in Joint Venture 0.7 Deferred tax assets Total non-current assets CURRENT ASSETS Inventories Trade and other receivables Other financial short-term assets Cash and cash equivalents Total current assets TOTAL ASSETS SHAREHOLDERS' EQUITY AND LIABILITIES Shareholders' equity attributable to the owners of the parent company Share capital Invested unrestricted equity fund Translation differences Retained earnings Total shareholders' equity NON-CURRENT LIABILITIES Deferred tax liabilities Other liabilities Total non-current liabilities CURRENT LIABILITIES Trade payables Total interest-bearing liabilities Tax liabilities Other liabilities Deferred gain Total current liabilities Total liabilities TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES
14 STATEMENT OF CHANGES IN EQUITY Consolidated statement of changes in equity on 30 September 2015 MEUR Share capital Translation differences Invested unrestricted equity fund Retained earnings Shareholders' equity Shareholders' equity 1 Jan Distribution of dividend Capital repayment Direct share issue Share based payments Exercise of share options Total comprehensive income for the period Shareholders' equity 30 Sep Consolidated statement of changes in equity on 30 September 2014 Share capital (MEUR) Translation differences (MEUR) Invested unrestricted equity fund (MEUR) Retained earnings (MEUR) Shareholders ' equity (MEUR) Shareholders' equity 1 Jan Distribution of dividend Capital repayment Direct share issue Share based payments Exercise of share options Total comprehensive income for the period Shareholders' equity 30 Sep
15 CASH FLOW STATEMENT MEUR 1-9/ / /2014 CASH FLOW FROM OPERATING ACTIVITIES Profit for the period Adjustments Change in working capital Interest paid and payments on other operating financial expenses Interest received Realised exchange rate gains and losses Income taxes paid Net cash flow from operating activities CASH FLOW FROM INVESTMENTS Investments in tangible and intangible assets Revenue from disposal of tangible and intangible assets Capital gain from the sale of liquid handling business Net investments in funds and deposits Net cash flow from investments CASH FLOW FROM FINANCING ACTIVITIES Rights issue Dividend payout Repayment of loans Net cash flow from financing activities Increase (+)/decrease (-) in cash and cash equivalents Cash and cash equivalents at the beginning of the period Effect of exchange rates on cash and cash equivalents Cash and cash equivalents at the end of the period RELATED PARTY TRANSACTIONS DURING JULY-SEPTEMBER 2015 Biohit Oyj B series shares subscribed with Stock Options I 2013 B A total number of 32,940 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 B during July 7 th, These shares have been entered into the trade register on August 7 th, 2015, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public 15
16 trading is expected to begin on NASDAQ OMX Helsinki as of August 10, 2015 together with the existing B- shares. The share subscription price was EUR per share respectively. The entire subscription price of EUR 74, will be credited to the reserve for invested non-restricted equity, and the company share capital remains unchanged. The shares have no nominal value. After the subscription the number of all Biohit Oyj's shares will rise to 14,348,533 shares (14,315,593) and B- shares will rise to 11,373,033 shares (11,340,093). The new shares will correspond to a percentage of 0.23% of Biohit Oyj's total number of shares and 0.05% of the voting rights after registration. The share subscription period with stock options I 2013 B began on June 1, 2015 and will end May 31, 2019 and 32,940 of the available 40,000 shares were subscribed. The option schemes are based on the Biohit Oyj board resolution of June 19, 2013 and the Annual General Meeting authorization of April 14, The terms and conditions of the option schemes with additional information are available on Biohit Oyj website at COLLATERAL, CONTINGENT LIABILITIES, AND OTHER COMMITMENTS 30 September September December 2014 Collateral granted on behalf of the parent company Corporate mortgages Collateral granted on behalf of the subsidiaries Guarantees Other liabilities Leasing commitments Due for payment in less than one year Due for payment in more than one year but less than five years Due for payment in more than five years Total Other rental commitments Due for payment in less than one year Due for payment in more than one year but less than five years Due for payment in more than five years Total Other contingent liabilities Collateral and contingent liabilities total
17 NEXT FINANCIAL REPORT Biohit will publish its financial reporting time table later this year. Helsinki, 22 October 2015 Biohit Oyj Board of Directors Additional information: CEO Semi Korpela, Biohit Oyj tel investor.relations@biohit.fi Biohit in brief Biohit Oyj is a globally operating Finnish biotechnology company. Biohit s mission is Innovating for Health we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/healthcare group. 17
PONSSE PLC, STOCK EXCHANGE RELEASE, 26 OCTOBER 2010, 9:00 a.m. PONSSE S INTERIM REPORT FOR 1 JANUARY 30 SEPTEMBER 2010
PONSSE PLC, STOCK EXCHANGE RELEASE, 26 OCTOBER 2010, 9:00 a.m. PONSSE S INTERIM REPORT FOR 1 JANUARY 30 SEPTEMBER 2010 - Net sales were EUR 171.8 (Q1-Q3/2009 EUR 98.9) million. - Q3 net sales were EUR
More informationSCANFIL PLC STOCK EXCHANGE RELEASE 27 APRIL 2007 8.30 a.m.
SCANFIL PLC STOCK EXCHANGE RELEASE 27 APRIL 2007 8.30 a.m. SCANFIL PLC'C INTERIM REPORT 1 JANUARY 31 MARCH 2007 - Turnover for the first quarter of 2007 totalled EUR 52,2 million (60,1 in the corresponding
More informationSCANFIL GROUP S INTERIM REPORT 1 JANUARY 30 SEPTEMBER 2009
SCANFIL PLC INTERIM REPORT 23 OCTOBER 2009 8.30 a.m. SCANFIL GROUP S INTERIM REPORT 1 JANUARY 30 SEPTEMBER 2009 January - September - Turnover for the first nine months of 2009 totalled EUR 149.2 million
More informationINTERIM REPORT JANUARY 1 SEPTEMBER 30, 2011
Q3 INTERIM REPORT JANUARY 1 SEPTEMBER 30, 2011 Helsinki, October 27, 2011 Fiskars Corporation Interim Report January 1 - September 30, 2011 October 27, 2011 Third quarter: Net sales and operating profit
More informationTECNOTREE CORPORATION INTERIM REPORT 1 JAN 31 MAR 2015 (UNAUDITED)
TECNOTREE CORPORATION INTERIM REPORT 1 JAN 31 MAR 2015 (UNAUDITED) 29 April 2015 at 8:30 am Tecnotree is a global supplier of telecom IT solutions, providing products and services for charging, billing,
More information7.5.2003 1 (11) INTERIM REPORT JANUARY 1 MARCH 31, 2003 A POSITIVE TURN IN THE RESULT DEVELOPMENT OF THE OKMETIC GROUP
7.5.2003 1 (11) INTERIM REPORT JANUARY 1 MARCH 31, 2003 A POSITIVE TURN IN THE RESULT DEVELOPMENT OF THE OKMETIC GROUP The Group s net sales for three months totalled 13.4 million euro (1Q2002: 14.9 million
More informationCondensed consolidated income statement
RESTATED AND PREVIOUSLY COMMUNICATED (OLD) QUARTERLY INFORMATION FOR Fortum signed the agreement to sell its Swedish distribution business on 13 March 2015, which concludes Fortum s divestment of its electricity
More informationRAKENTAJAIN KONEVUOKRAAMO OYJ STOCK EXCHANGE RELEASE 10 MAY 2005, at 10.30 hrs RAKENTAJAIN KONEVUOKRAAMO OYJ S INTERIM REPORT Q1/2005
RAKENTAJAIN KONEVUOKRAAMO OYJ STOCK EXCHANGE RELEASE 10 MAY 2005, at 10.30 hrs RAKENTAJAIN KONEVUOKRAAMO OYJ S INTERIM REPORT Q1/2005 - Turnover, EUR 17.0 million (EUR 15.4 million) - A 10.3 per cent increase
More informationInterim Report January-March. A significant result improvement
Interim Report January-March A significant result improvement ETTEPLAN OYJ INTERIM REPORT MAY 7, 2015, AT 2:00 PM ETTEPLAN Q1: A SIGNIFICANT RESULT IMPROVEMENT Review period January-March 2015 The Group
More informationSSH COMMUNICATIONS SECURITY CORPORATION INTERIM REPORT RELEASE, JANUARY 1 SEPTEMBER 30, 2015
SSH COMMUNICATIONS SECURITY CORPORATION INTERIM REPORT RELEASE October 22, AT 9:00 A.M SSH COMMUNICATIONS SECURITY CORPORATION INTERIM REPORT RELEASE, JANUARY 1 SEPTEMBER 30, July September : +12.8 % net
More informationIn addition, Outokumpu has adopted the following amended standards as of January 1, 2009:
1. Corporate information Outokumpu Oyj is a Finnish public limited liability company organised under the laws of Finland and domiciled in Espoo. The parent company, Outokumpu Oyj, has been listed on the
More informationInterim report April-June 2003
Interim report April-June 2003 Pre-tax profit for the second quarter amounted to SEK -34m, which is a SEK 30m improvement compared to last year (SEK -64m). Software revenue grew by 5% during the second
More informationINTERIM REPORT 1.1.-30.9.2004
INTERIM REPORT 1.1.-30.9.2004 RAUTE OYJ 1 (9) RAUTE OYJ S INTERIM REPORT FOR JANUARY 1 - SEPTEMBER 30, 2004 Net sales MEUR 60.6 (MEUR 55.1) and operating profit MEUR 4.8 (MEUR -7.6) grew markedly. Net
More informationTECNOTREE CORPORATION FINANCIAL REPORT 1 JAN 31 DEC 2014 (UNAUDITED)
TECNOTREE CORPORATION FINANCIAL REPORT 1 JAN 31 DEC 2014 (UNAUDITED) 30 January 2015 at 8:30 am Tecnotree is a global supplier of telecom IT solutions, providing products and services for charging, billing,
More informationTO OUR SHAREHOLDERS PROFITABLE GROWTH COURSE INTERNATIONALIZATION FURTHER EXTENDED US MARKET IN FOCUS
QUARTERLY STATEMENT AS OF MARCH 31, 2015 TO OUR SHAREHOLDERS Patrik Heider, Spokesman of the Executive Board and CFOO The Nemetschek Group has made a dynamic start in the 2015 financial year and continues
More informationAbbey plc ( Abbey or the Company ) Interim Statement for the six months ended 31 October 2007
Abbey plc ( Abbey or the Company ) Interim Statement for the six months ended 31 October 2007 The Board of Abbey plc reports a profit before taxation of 18.20m which compares with a profit of 22.57m for
More informationASPOCOMP GROUP Oyj STOCK EXCHANGE BULLETIN July 28,2000 14.30PM 1(7)
ASPOCOMP GROUP Oyj STOCK EXCHANGE BULLETIN July 28,2000 14.30PM 1(7) ASPOCOMP INTERIM REPORT JANUARY 1 JUNE 30, 2000 Net sales for the first six months of the year increased 25.3 % totalling EUR 122.2
More informationStock Exchange Release 8 May 2003, at 9 am
Sponda Plc Stock Exchange Release 8 May 2003, at 9 am Interim Report January-March 2003 SPONDA S FIRST QUARTER RESULT AS EXPECTED Sponda Group recorded a first-quarter net profit of EUR 6.9 (79.5) million.
More informationDigia s first quarter 2013: Closure of contract engineering business continued to affect the net sales, leading to slightly negative operating profit
Digia s first quarter 2013: Closure of contract engineering business continued to affect the net sales, leading to slightly negative operating profit Summary January-March Consolidated net sales: EUR 23.5
More informationTO OUR SHAREHOLDERS DYNAMIC FIRST HALF YEAR
HALF YEAR REPORT AS OF JUNE 30, 2015 TO OUR SHAREHOLDERS Patrik Heider, Spokesman of the Executive Board and CFOO The Nemetschek Group maintained its dynamic development from the first quarter of 2015
More informationSSH COMMUNICATIONS SECURITY CORPORATION FINANCIAL STATEMENT RELEASE, JANUARY 1 MARCH 31, 2016
SSH COMMUNICATIONS SECURITY CORPORATION FINANCIAL STATEMENT RELEASE April 21, 2016 AT 9:00 A.M SSH COMMUNICATIONS SECURITY CORPORATION FINANCIAL STATEMENT RELEASE, JANUARY 1 MARCH 31, 2016 January March
More informationCONSOLIDATED INTERIM FINANCIAL STATEMENTS
CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND GROUP INTERIM MANAGEMENT REPORT SECOND QUARTER OF 2008 JUNE 30, 2008 FRANCONOFURT AG FRANKFURT AM MAIN FRANCONOFURT AG, FRANKFURT AM MAIN CONSOLIDATED INTERIM
More informationSOLTEQ PLC S INTERIM REPORT 1.1.-30.6.2013
Stock Exchange Bulletin 1 (13) SOLTEQ PLC S INTERIM REPORT 1.1.-30.6.2013 Solteq Plc Stock Exchange Bulletin - Solteq Plc s turnover increased 2.2 per cent and totalled 19.7 million euros (19.3 million
More informationConsolidated Statement of Profit or Loss (in million Euro)
Consolidated Statement of Profit or Loss (in million Euro) Q3 2014 Q3 2015 % change 9m 2014 9m 2015 % change Revenue 636 661 3.9% 1,909 1,974 3.4% Cost of sales (440) (453) 3.0% (1,324) (1,340) 1.2% Gross
More informationApetit Plc Interim Report, January June 2015
Apetit Plc Interim Report, January June 2015 Second quarter (April June) Consolidated net sales were up on the previous year and amounted to EUR 100.2 (98.1) million. Operating profit excluding non-recurring
More informationSTOCK EXCHANGE RELEASE October 23, 2003, at 3.40 p.m. RAUTE OYJ S INTERIM REPORT FOR JANUARY 1 SEPTEMBER 30, 2003
1 RAUTE OYJ Translation STOCK EXCHANGE RELEASE October 23, 2003, at 3.40 p.m. RAUTE OYJ S INTERIM REPORT FOR JANUARY 1 SEPTEMBER 30, 2003 The Raute Group posted consolidated net sales of MEUR 55.1 (MEUR
More informationHALF YEAR REPORT AS OF JUNE 30
2 0 1 4 HALF YEAR REPORT AS OF JUNE 30 T O O U R S H A R E H O L D E R S Dear shareholders, ladies and gentlemen, The Nemetschek Group continued its successful development in the second quarter of 2014
More informationNedSense enterprises n.v. Condensed consolidated Interim financial statements
NED NEDSENSE enterprises n.v. NedSense enterprises n.v. Condensed consolidated Interim financial statements 30 June 2012 NedSense enterprises n.v. Half-year Report 2012 (unaudited) Report of the Board
More informationTeleste Corporation Interim Report 1.1. 30.9.2002
Teleste Corporation Interim Report 1.1. 30.9.2002 Teleste Corporation Interim Report 1.1. 30.9.2002 The decline in network operators investments in Teleste s core business has not eased off Market outlook
More informationHALF-YEAR FINANCIAL REPORT FOR THE PERIOD JANUARY JUNE 2016
PRESS RELEASE HALF-YEAR FINANCIAL REPORT FOR THE PERIOD JANUARY JUNE 2016 DETERIORATION IN VIKING LINE S RESULTS DUE TO EXTENSIVE VESSEL MODERNIZATIONS Consolidated sales of the Viking Line Group for the
More information1. Accounting policies for consolidated financial statements
1 1. Accounting policies for consolidated financial statements Corporate information The Sanoma Group comprises three reporting segments: Media, News and Learning. The Media segment consists of four strategic
More informationJuly 29, 2008 at 9.00am. (Unaudited figures. Unless otherwise stated comparisons are made to the same period one year ago. The currency is euro.
F-SECURE CORPORATION Stock Exchange Release July 29, 2008 at 9.00am F-Secure Group January 1 - June 30, 2008 Financial Results Solid overall growth, good profitability (Unaudited figures. Unless otherwise
More informationDiluted net income per share (Yen) 90.03 129.05. Net assets per share assets. Equity
Summary of Consolidated Financial Results for the Nine months Ended December 31, 2008 February 3, 2009 Listed company name : Sysmex Corporation Code : 6869 Listed stock exchanges : Tokyo Stock Exchange
More informationFOR IMMEDIATE RELEASE 28 September 2015 BOND INTERNATIONAL SOFTWARE PLC UNAUDITED INTERIM RESULTS
FOR IMMEDIATE RELEASE 28 September 2015 BOND INTERNATIONAL SOFTWARE PLC UNAUDITED INTERIM RESULTS Bond International Software Plc ( the Group ), the specialist provider of software for the international
More informationDIGIA PLC Q1 2015: NET SALES AND OPERATING PROFIT INCREASE ON THE BACK OF QT'S VIGOROUS GROWTH (30.9%)
DIGIA PLC Q1 2015: NET SALES AND OPERATING PROFIT INCREASE ON THE BACK OF QT'S VIGOROUS GROWTH (30.9%) Summary January-March Consolidated net sales: EUR 25.7 (24.0) million, up 7.1 per cent Operating profit
More informationHalf Year Financial Statement And Announcement for the Period Ended 31/12/2010
AUSSINO GROUP LTD Company Registration No.: 199100323H Half Year Financial Statement And Announcement for the Period Ended 31/12/2010 PART I - INFORMATION REQUIRED FOR ANNOUNCEMENTS OF QUARTERLY (Q1, Q2
More informationAsia Pacific Wire & Cable Company Reports Full Year 2013 Financial Results
Asia Pacific Wire & Cable Company Reports Full Year 2013 Financial Results Gross profit was $51.8 million, an increase of 2.6% from $50.5 million in FY2012 Cash flows from operations was $20.6 million,
More informationFOR IMMEDIATE RELEASE 17 September 2013 BOND INTERNATIONAL SOFTWARE PLC UNAUDITED INTERIM RESULTS
FOR IMMEDIATE RELEASE 17 September 2013 BOND INTERNATIONAL SOFTWARE PLC UNAUDITED INTERIM RESULTS Bond International Software Plc ( the Group ), the specialist provider of software for the international
More information2015 Quarterly Report II
2015 Quarterly Report II 2 Key data Eckert & Ziegler 01 06/2015 01 06/2014 Change Sales million 69.0 61.9 + 11 % Return on revenue before tax % 16 % 9 % + 87 % EBITDA million 15.6 9.7 + 61 % EBIT million
More informationConsolidated Financial Statements for the Third Quarter of the Fiscal Year Ending March 31, 2008
February 5, 2008 Consolidated Financial Statements for the Third Quarter of the Fiscal Year Ending March 31, 2008 Corporate Name: Alfresa Holdings Corporation (Code: 2784, 1st sections of Tokyo Stock Exchange
More informationFinancial Results. siemens.com
s Financial Results Fourth Quarter and Fiscal 2015 siemens.com Key figures (in millions of, except where otherwise stated) Volume Q4 % Change Fiscal Year % Change FY 2015 FY 2014 Actual Comp. 1 2015 2014
More informationConsolidated balance sheet
83 Consolidated balance sheet December 31 Non-current assets Goodwill 14 675.1 978.4 Other intangible assets 14 317.4 303.8 Property, plant, and equipment 15 530.7 492.0 Investment in associates 16 2.5
More informationASPOCOMP GROUP Oyj STOCK EXCHANGE BULLETIN Feb 16,2000 at 10.15AM1(6)
ASPOCOMP GROUP Oyj STOCK EXCHANGE BULLETIN Feb 16,2000 at 10.15AM1(6) ASPOCOMP GROUP FINANCIAL PERFORMANCE 1999 Operating profit after depreciation totalled EUR 21.5 million (EUR 11.8 million) and after
More informationITELLA CORPORATION STOCK EXCHANGE RELEASE JULY 25, 2012, AT 12:00 NOON (EET)
ITELLA CORPORATION STOCK EXCHANGE RELEASE JULY 25, 2012, AT 12:00 NOON (EET) Itella Corporation Interim Report Q2/2012 January June 2012 Itella Group s net sales in January June amounted to EUR 958.5 (932.6)
More informationNote 2 SIGNIFICANT ACCOUNTING
Note 2 SIGNIFICANT ACCOUNTING POLICIES BASIS FOR THE PREPARATION OF THE FINANCIAL STATEMENTS The consolidated financial statements have been prepared in accordance with International Financial Reporting
More informationFINANCIAL RESULTS FOR THE PERIOD 1 JANUARY 31 MARCH 2003
FINANCIAL RESULTS FOR THE PERIOD 1 JANUARY 31 MARCH 2003 The consolidated income after financial items amounted to SEK 75.3 (3.3) million for the period, including capital gain of SEK 90.6 (30.8) million.
More informationRAPALA ANNUAL ACCOUNTS 2011: GOOD YEAR IN CHALLENGING BUSINESS ENVIRONMENT
STOCK EXCHANGE RELEASE 1(15) RAPALA ANNUAL ACCOUNTS : GOOD YEAR IN CHALLENGING BUSINESS ENVIRONMENT Net sales for the quarter increased by 1% to a new fourth quarter record of 60.8 (60.4 ). Net sales for
More informationOverview of the key figures for the first half of the year
Half-Year Report 2015 Q2 Revenues increase in the first half of the year by 23% EBIT increased by 1.5 million euros compared to the previous year Order book is growing Overall annual forecast remains unchanged
More informationConsolidated Statements of Profit or Loss Ricoh Company, Ltd. and Consolidated Subsidiaries For the Years Ended March 31, 2014 and 2015
Consolidated Statements of Profit or Loss Sales: Products 1,041,794 1,071,446 8,928,717 Post sales and rentals 1,064,555 1,068,678 8,905,650 Other revenue 89,347 91,818 765,150 Total sales 2,195,696 2,231,942
More informationWILEX AG: Interim management statement on the first quarter of 2016
WILEX AG: Interim management statement on the first quarter of 2016 Munich, Germany, 14 April 2016. WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today reported on the first three months of the 2016 financial
More informationConsolidated Statement of Financial Position
INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 30 JUNE 2014 Consolidated Statement of Financial Position in CHF 1,000 Note 30 June 2014 31 December 2013 (unaudited) (audited) Assets Non-current assets
More informationEmployees Employees as at 31 August 53 44 20.5 Employees average during the reporting period 52 44 18.2
9M 2007 9M 2006 Change in % Earnings key figures in EUR 000 Other operating income 2,158 966 123.4 Operating expenses (19,486) (13,149) 48.2 of which research and development (16,606) (10,527) 57.8 Operating
More informationPoste Italiane: growth in revenue and operating profit. Board of Directors approves Half Year results
Poste Italiane: growth in revenue and operating profit Board of Directors approves Half Year results Approves filing of regulatory files for a listing and the adoption of a new governance code Total revenues:
More informationBrief Report on Closing of Accounts (connection) for the Term Ended March 31, 2007
MARUHAN Co., Ltd. Brief Report on Closing of (connection) for the Term Ended March 31, 2007 (Amounts less than 1 million yen omitted) 1.Business Results for the term ended on March, 2007 (From April 1,
More informationFinancial Report 9M 2014
Financial Report 9M 2014 1 von 10 12.11.14 13:19 1. Financial Summary Income (in TEUR) 9M 2014 9M 2013 Revenues 9,485 9,992 Software & Subscriptions 8,668 8,127 Services 817 1,865 EBIT 2,926 1,051 as a
More informationNet interest-bearing debt at 30 June 2015 was DKK 560 million (30 June 2014: DKK 595 million).
H+H International A/S Interim financial report Company Announcement No. 327, 2015 H+H International A/S Dampfærgevej 3, 3rd Floor 2100 Copenhagen Ø Denmark Tel. +45 35 27 02 00 info@hplush.com www.hplush.com
More informationInterim Financial Statements
[Type text] Interim Financial Statements KCA Deutag Alpha Limited For the twelve months ended 31 December 2015 Page 1 of 11 Table of Contents Consolidated income statement... 3 Consolidated statement of
More informationPRELIMINARY UNAUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2014
DENSITRON TECHNOLOGIES PLC PRELIMINARY UNAUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2014 Densitron Technologies plc ( Densitron or the Company or the Group ), the designer, developer and distributor
More informationFINANCIAL REPORT H1 2014
FINANCIAL REPORT H1 2014 HIGH SPEED BY PASSION 02_Key Figures 03_Group Status Report 05_Consolidated Financial Statements 10_Notes 11_Declaration of the Legal Representatives 02 PANKL KEY FIGURES EARNING
More informationVASSETI (UK) PLC CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2013
CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED 30 JUNE 2013 INTERIM MANAGEMENT REPORT (UNAUDITED) FOR THE 6 MONTHS ENDED 30 JUNE 2013 1. Key Risks and uncertainties Risks and uncertainties
More informationCembre (a STAR listed company): approved a distribution of a 0.26 dividend per share
Joint-stock Company Main Office: Via Serenissima, 9 25135 Brescia VAT no: 00541390175 Share Capital: 8,840,000 fully paid up Registration no: 00541390175 tel.: +39 0303692.1 fax: +39 0303365766 Press release
More informationInVision AG Workforce Management Cloud Services Call Center Training. Financial Report 9M 2014
Financial Report 9M 2014 Seite 1 von 7 1. Financial Summary Income (in TEUR) 9M 2014 9M 2013 Revenues 9,485 9,992-5% Software & Subscriptions 8,668 8,127 +7% Services 817 1,865-56% EBIT 2,926 1,051 +178%
More informationConsolidated Statement of Profit or Loss (in million Euro)
Consolidated Statement of Profit or Loss (in million Euro) Q3 2013 Q3 2014 % change 9m 2013 9m 2014 % change Revenue 689 636-7.7% 2,126 1,909-10.2% Cost of sales (497) (440) -11.5% (1,520) (1,324) -12.9%
More informationCondensed consolidated interim report for the third quarter
Condensed consolidated interim report for the third quarter 2011 Beginning of interim period: 1.1.2011 End of interim period: 30.09.2011 Beginning of financial year: 1.1.2011 End of financial year: 31.12.2011
More informationConsolidated Financial Results for Fiscal Year 2013 (April 1, 2013 March 31, 2014)
Consolidated Financial Results for Fiscal Year 2013 (April 1, 2013 March 31, 2014) 28/4/2014 Name of registrant: ShinMaywa Industries, Ltd. Stock Exchange Listed: Tokyo Code number: 7224 (URL: http://www.shinmaywa.co.jp
More informationcondensed consolidated interim financial statements 2015
January march 2015 condensed consolidated interim financial statements 2015 (unaudited) contents 1. Income Statement 1 2. Statement of Comprehensive Income 2 3. Balance Sheet 3 4. Statement of Changes
More informationInternational Accounting Standard 7 Statement of cash flows *
International Accounting Standard 7 Statement of cash flows * Objective Information about the cash flows of an entity is useful in providing users of financial statements with a basis to assess the ability
More informationConsolidated Statement of Profit or Loss
Consolidated Statement of Profit or Loss Sales: Products 864,699 1,041,794 $ 10,114,505 Post sales and rentals 941,610 1,064,555 10,335,485 Other revenue 79,686 89,347 867,447 Total sales 1,885,995 2,195,696
More informationNet sales Operating income Ordinary income Net income
MORITO CO., LTD. Financial Statement (Unaudited) For the Third Quarters of the Fiscal Year ended November 30, 2015 (Translated from the Japanese original) October 9, 2015 Corporate Information Code: 9837
More information(April 1, 2015 June 30, 2015)
Financial Results Summary of Consolidated Financial Results For the Three-month Period Ended June 30, 2015 (IFRS basis) (April 1, 2015 June 30, 2015) *This document is an English translation of materials
More informationAddresses. Corporate Equity Partners AG. Subsidiaries. Company s Registered Head Office: Obmoos 4 CH 6301 Zug Switzerland. The Fantastic IP GmbH
Corporate Equity Partners Group 9 Month Financial Statements 2009 Addresses Corporate Equity Partners AG Company s Registered Head Office: Obmoos 4 CH 6301 Zug Switzerland Subsidiaries The Fantastic IP
More informationFinancial Statements and Board of Directors Report for 2013
Financial Statements and Board of Directors Report for 2013 get the world Contents Key indicators...4 Definitions of key indicators...5 Net sales by business...6 Operating profit excluding non-recurring
More informationFINANCIAL STATEMENTS 2011
FINANCIAL STATEMENTS FINANCIAL STATEMENTS Report of the Board of Directors, financial period nebula January oy:n 1 December Tilinpäätös 31, Ownership structure changes, board of directors and auditor With
More informationThe ReThink Group plc ( ReThink Group or the Group ) Unaudited Interim Results. Profits double as strategy delivers continued improved performance
The ReThink Group plc ( ReThink Group or the Group ) Unaudited Interim Results Profits double as strategy delivers continued improved performance The Group (AIM: RTG), one of the UK s leading recruitment
More informationRAPALA VMC CORPORATION FINANCIAL STATEMENTS 2012
FINANCIAL STATEMENTS 2012 RAPALA VMC CORPORATION FINANCIAL STATEMENTS 2012 INDEX RAPALA VMC CORPORATION FINANCIAL STATEMENTS 2012 Review of the Board of Directors Auditor s Report Consolidated Financial
More informationHow To Calculate Profit From A Profit From An Investment
TO: THE STOCKHOLDERS OF THE GLEANER COMPANY LIMITED CONSOLIDATED INCOME STATEMENT FOR NINE MONTHS ENDED SEPTEMBER 30, 2015 Notes Three Months Three Months (Audited) Twelve Months ended Dec 31, 2014 Restated
More informationGroup 9-month report Bastei Lübbe AG 1 Apr - 31 Dec 2015
Group 9-month report Bastei Lübbe AG 1 Apr - 31 Dec 2015 At a Glance Key figures (IFRS) 01/04/2015-2015 01/04/- Change in % Business development in million Group turnover 79.4 86.8-8.5 % EBITDA 14.0 11.5
More informationInvestment service companies
2015 Investment service companies 2015, 1st quarter Net operating profit of investment service companies grew in January to March from the year before The net operating profit of investment service companies
More informationStock Exchange Release February 24, 2011 at 8.00 am (CET+1) 1/7
February 24, 2011 at 8.00 am (CET+1) 1/7 Kemira Oyj: Notice of Annual General Meeting The shareholders of Kemira Oyj ( Kemira ) are invited to the Annual General Meeting to be held on Tuesday, March 22,
More informationSTONESOFT CORP. STOCK EXCHANGE RELEASE APRIL 28,2006 AT 9.00 AM STONESOFT CORP.'S INTERIM REPORT FOR JANUARY-MARCH 2006
STONESOFT CORP. STOCK EXCHANGE RELEASE APRIL 28,2006 AT 9.00 AM STONESOFT CORP.'S INTERIM REPORT FOR JANUARY-MARCH 2006 The sales of StoneGate products increased by 12 % during the first quarter. SUMMARY
More informationNet cash balances at the year-end were 2.87 million (2014: 2.15 million) and total capital expenditure during the year was 626,000 (2014: 386,000).
Preliminary Announcement for the year ended 30 September 2015 Chairman s Statement The result for the year to 30 September 2015 is a net Profit before Taxation of 1,869,000 (2014: 1,333,000), on Revenues
More informationUNIVERSAL OUTDOOR MEDIA GROUP PLC SEMI- ANNUAL ACCOUNTS STATEMENT AND MANAGEMENT REPORT (Unaudited) 31 DECEMBER 2014
UNIVERSAL OUTDOOR MEDIA GROUP PLC SEMI- ANNUAL ACCOUNTS STATEMENT AND MANAGEMENT REPORT (Unaudited) INTERIM MANAGEMENT REPORT Chairman Statement Your Board announces the Group s unaudited interim results
More informationEU Supply Plc ( EU Supply, the Company or the Group ) Interim results for the six months ended 30 June 2015
9 September EU Supply Plc ( EU Supply, the Company or the Group ) Interim results for the six months ended EU Supply, the e-procurement SaaS provider, is pleased to announce its unaudited interim results
More informationAssetCo plc ( AssetCo or the Company ) Results for the six-month period ended 31 March 2012
Issued on behalf of AssetCo plc Date: Friday 29 June 2012 Immediate Release Statement by the Chairman, Tudor Davies AssetCo plc ( AssetCo or the Company ) Results for the six-month period ended 31 March
More informationNOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS. Actuarial Gains and Losses, Group Plans and Disclosures
08 TCL Multimedia Technology Holdings Limited INTERIM RESULTS NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. Basis of preparation The Directors are responsible for the preparation of the Group
More informationGROUP (Unaudited) Three Month Jan Mar. 2015 $000 s. Notes
TO: THE STOCKHOLDERS OF THE GLEANER COMPANY LIMITED CONSOLIDATED INCOME STATEMENT FOR THREE MONTHS ENDED MARCH 31, 2015 Notes Three Month Jan Mar. 2015 Jan Mar. 2014 Restated (Audited) Twelve Months ended
More informationJuly September 2013. July September 2014
Interim Report Interim Report Sales in the quarter increased to SEK 225.1 (216.9) million. In local currencies the decrease was 1.1 per cent. Operating profit for the quarter was SEK 12.9 (5.7) million.
More informationCapMan Plc Stock Options 2013
CapMan Plc Stock Options 2013 The Board of Directors of CapMan Plc (the Board of Directors) has at its meeting on 25 February 2013 resolved to propose to the Annual General Meeting of Shareholders of CapMan
More informationOP MORTGAGE BANK Stock exchange release 27 April 2016 Interim Report. OP Mortgage Bank Interim Report for January March 2016
OP MORTGAGE BANK Stock exchange release 27 April 2016 Interim Report OP Mortgage Bank Interim Report for January March 2016 OP Mortgage Bank (OP MB) is part of OP Financial Group and its role is to raise,
More informationTravel24.com AG. Quarterly Report Q1 2015
Travel24.com AG Quarterly Report Q1 2015 2 Selected Key Group Data January 1 - March 31 Change In thousands of euro 2015 2014 % Revenue 4,494 7,810-42 % EBIT 806 1,231-35 % Net profit 66 518-87 % Earnings
More informationADVANCED SYSTEMS AUTOMATION LIMITED (Company Registration No: 198600740M) (Incorporated in the Republic of Singapore)
Financial Statements and Related Announcement::Second Quarter and/ or Half Yearly... http://infopub.sgx.com/apps?a=cow_corpannouncement_content&b=announcem... Page 1 of 1 8/13/2015 Financial Statements
More informationRestamax Group - A Guide to the Finnish Business Environment in 2015
INTERIM REPORT Q1/2015 RESTAMAX INTERIM REPORT Q1 2015 THE GROUP S STRONG GROWTH CONTINUED AND PROFITABILITY IMPROVED IN JANUARY MARCH 2015 January March 2015 in brief Figures in parentheses refer to the
More informationHowellust
Year-end report 1 January 31 December 2013 Net sales rose to SEK 479.4 M (433.8), up approximately 12%.* Order bookings totalled SEK 460.5 M (447.6), up about 4%.* Operating profit amounted to SEK 48.0
More informationIndian Accounting Standard (Ind AS) 7 Statement of Cash Flows
Contents Indian Accounting Standard (Ind AS) 7 Statement of Cash Flows Paragraphs OBJECTIVE SCOPE 1 3 BENEFITS OF CASH FLOW INFORMATION 4 5 DEFINITIONS 6 9 Cash and cash equivalents 7 9 PRESENTATION OF
More informationQuarter Report 2014 ESSANELLE HAIR GROUP AG
Quarter Report 2014 ESSANELLE HAIR GROUP AG Q1 2 Q1/2014 ESSANELLE HAIR GROUP KEY FIGURES for 1 January to 31 March 2014/2013 (IFRS) million 2014 2013 Change* Consolidated sales 32.3 30.8 +4.7% essanelle
More informationEXPLANATORY NOTES. 1. Summary of accounting policies
1. Summary of accounting policies Reporting Entity Taranaki Regional Council is a regional local authority governed by the Local Government Act 2002. The Taranaki Regional Council group (TRC) consists
More informationFIRST QUARTER 2005. Highlights from first quarter 2005 include: Operating profit 10 MNOK (42 MNOK last year)
FIRST QUARTER 2005 Highlights from first quarter 2005 include: Revenues 599 MNOK (+1 percent relative to first quarter 2004) Operating profit 10 MNOK (42 MNOK last year) Acquisition of Orwak Group completed
More informationNovember 4, 2015 Consolidated Financial Results for the Second Quarter of Fiscal Year 2015 (From April 1, 2015 to September 30, 2015) [Japan GAAP]
November 4, 2015 Consolidated Financial Results for the Second Quarter of Fiscal Year 2015 (From April 1, 2015 to September 30, 2015) [Japan GAAP] Company Name: Idemitsu Kosan Co., Ltd. (URL http://www.idemitsu.com)
More informationInterim Report for the period 1 January 31 March 2015
Interim Report for the period 1 January 31 March 2015 ALL FIGURES IN THIS REPORT ARE EXPRESSED IN SEK, UNLESS STATED OTHERWISE. FIGURES IN PARENTHESES REFER TO THE CORRESPONDING FIGURES FOR THE PREVIOUS
More informationThird Quarter 2014 Financial Results
Third Quarter 2014 Financial Results Core pre-provision income up by 8.0% in the third quarter 2014. Operating expenses further down by 3.7% q-o-q and 11.4% y-o-y on a comparable basis. Accelerated provisioning
More information